(1E,4Z,6E)-1,7-bis(4-(dimethylamino)phenyl)-5-hydroxyhepta-1,4,6-trien-3-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: (1E,4Z,6E)-1,7-bis(4-(dimethylamino)phenyl)-5-hydroxyhepta-1,4,6-trien-3-one
• 英文别名: 1,7-Bis(4-(dimethylamino)phenyl)-5-hydroxyhepta-1,4,6-trien-3-one；(1E,4Z,6E)-1,7-bis[4-(dimethylamino)phenyl]-5-hydroxyhepta-1,4,6-trien-3-one
• 化学式: C₂₃H₂₆N₂O₂
• 分子量: 362.472
• InChiKey: JLNWRDOLIIJBPC-RFYMSPFYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (1E,4Z,6E)-1,7-bis(4-(dimethylamino)phenyl)-5-hydroxyhepta-1,4,6-trien-3-one 在 三氟化硼乙醚 作用下， 以 neat (no solvent) 为溶剂， 以89%的产率得到2,2-difluoro-4,6-di(p-dimethylaminostyryl)-1,3,2-dioxaborine
  参考文献：
  名称：

  Mechanochemical synthesis of 2,2-difluoro-4, 6-bis(β-styryl)-1,3,2-dioxaborines and their use in cyanide ion sensing

  摘要：

  摘要：将芳基醛转化为1,7-二芳基-5-羟基庚烷-1,4,6-三烯-3-酮（姜黄素类化合物），并描述了利用BF₃-Et₂O进行这些产物的机械化学环化反应，制备2,2-二氟-4,6-双(β-苯乙烯基)-1,3,2-二氧硼杂环。研究了2,2-二氟-4,6-双(β-苯乙烯基)-1,3,2-二氧硼杂环对氰离子的感应能力，发现与芳基环上的取代基团相关，需要一个羟基取代基，最好是位于介入碳桥的para位置。

  DOI：

  10.1515/hc-2015-0096
• 作为产物：
  描述：

  对二甲氨基苯甲醛 、 乙酰丙酮 在 硼酸三丁酯 、 正丁胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.5h， 以68%的产率得到(1E,4Z,6E)-1,7-bis(4-(dimethylamino)phenyl)-5-hydroxyhepta-1,4,6-trien-3-one
  参考文献：
  名称：

  A curcumin-based molecular probe for near-infrared fluorescence imaging of tau fibrils in Alzheimer's disease

  摘要：

  近年来，人们对近红外（NIR）荧光成像进行了越来越多的研究，用于早期诊断阿尔茨海默病（AD）的tau纤维。

  DOI：

  10.1039/c5ob01847a

文献信息

• A curcumin-based molecular probe for near-infrared fluorescence imaging of tau fibrils in Alzheimer's disease
  作者：Kwang-su Park、Yujin Seo、Mi Kyoung Kim、Kyungdo Kim、Yun Kyung Kim、Hyunah Choo、Youhoon Chong

  DOI：10.1039/c5ob01847a

  日期：——

  In recent years, there has been growing interest in the near-infrared (NIR) fluorescence imaging of tau fibrils for the early diagnosis of Alzheimer's disease (AD).

  近年来，人们对近红外（NIR）荧光成像进行了越来越多的研究，用于早期诊断阿尔茨海默病（AD）的tau纤维。
• COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR
  申请人：HUMAN BIOMOLECULAR RESEARCH INSTITUTE

  公开号：US20160038641A1

  公开（公告）日：2016-02-11

  Compositions of small molecules, matrices, and isolated cells including methods of preparation, and methods for differentiation, transdifferentiation, and proliferation of animal cells into the osteoblast blast cell lineage were described. Examples of osteogenic materials that were administered to cells or co-cultured with cells are represented by compounds of Formula II, IV, and VI independently or preferably in combination with a matrix to afford bone cells. Small molecule-stimulated cells were also combined with a matrix, placed with a cellular adhesive or material carrier and implanted to a site in an animal for bone repair. Matrix pretreated with compounds of Formula II, IV, and VI were also used to cause cells to migrate to the matrix that is of use for therapeutic purposes.

  描述了由小分子、基质和孤立细胞组成的组合物，包括制备方法，以及动物细胞分化、转分化和增殖成骨母细胞谱系的方法。给细胞施加的或与细胞共培养的成骨材料的示例由独立或首选与基质组合的Formula II、IV和VI化合物代表。受小分子刺激的细胞还与基质结合，与细胞粘合剂或材料载体一起植入到动物体内的部位进行骨修复。预先用Formula II、IV和VI化合物处理的基质也被用于导致细胞迁移到用于治疗目的的基质上。
• Diagnostic Methods and Genetic Markers for Alzheimer Disease
  申请人：Cashman John R.

  公开号：US20090263492A1

  公开（公告）日：2009-10-22

  Disclosed are methods for identifying individuals suffering from a CNS disorder (including Alzheimer's Disease, behavioral disorders, and the like) that could be treated with a CNS drug with greater therapeutic efficacy and lower side effects and the compounds useful for such treatment. Also disclosed are methods for predicting the efficacy of a drug candidate for the treatment of a CNS disorder. The technology is also applicable to drug discovery for use in animal models of neurodegenerative diseases.

  本发明涉及一种识别患有中枢神经系统疾病（包括阿尔茨海默病、行为障碍等）的个体，以及可用于治疗这些疾病的中枢神经系统药物，其具有更高的治疗效果和更低的副作用的方法和化合物。本发明还涉及一种预测用于治疗中枢神经系统疾病的药物候选品的疗效的方法。该技术还适用于用于神经退行性疾病动物模型的药物发现。
• SMALL MOLECULE IMMUNOMODULATORS FOR ALZHEIMER'S DISEASE
  申请人：Cashman John R.

  公开号：US20120040976A1

  公开（公告）日：2012-02-16

  Disclosed are methods for identifying individuals suffering from a CNS disorder (including Alzheimer's Disease, ALS, behavioral disorders, and the like) that could be treated with a CNS drug with greater therapeutic efficacy and lower side effects and the compounds useful for such treatment. Also disclosed are methods for predicting the efficacy of a drug candidate for the treatment of a CNS disorder. The technology is also applicable to drug discovery for evaluation in animal models of neurodegenerative diseases.

  本发明涉及识别患有中枢神经系统疾病（包括阿尔茨海默病、肌萎缩性侧索硬化症、行为障碍等）的个体，这些个体可以通过使用中枢神经系统药物进行治疗，其治疗效果更好，副作用更小，以及用于此类治疗的化合物。本发明还涉及预测治疗中枢神经系统疾病的候选药物的疗效的方法。该技术还适用于药物发现，以在神经退行性疾病动物模型中进行评估。
• THERAPEUTIC COMPOSITIONS COMPRISING A COMBINATION OF A HARMINE AND ISOVANILLIN COMPONENT
  申请人：Ions Pharmaceutical S.À R.L.

  公开号：EP3275465A1

  公开（公告）日：2018-01-31

  Human therapeutic treatment compositions comprise the combination of at least one harmine component, and at least one isovanillin component, wherein the components of the composition are different. The compositions are effective for the treatment of human conditions, especially human cancers.

  人类治疗组合物由至少一种禾本科成分和至少一种异香兰素成分组合而成，其中组合物的成分各不相同。这些组合物可有效治疗人类疾病，尤其是人类癌症。